131741-08-7 Usage
Description
Simendan, also known as the racemic mixture of Levosimendan (L378000), is a pharmaceutical compound that serves as a positive inotropic agent with vasodilating activity. It is characterized by its ability to enhance the contractility of the heart while simultaneously causing blood vessel dilation, making it a valuable asset in the treatment of various cardiovascular conditions.
Uses
Used in Pharmaceutical Industry:
Simendan is used as a positive inotropic agent for improving heart contractility in patients with heart failure or other cardiovascular conditions. Its dual action of increasing cardiac output and reducing afterload makes it a beneficial treatment option.
Simendan is also used as a vasodilator for promoting blood vessel dilation, which can help alleviate the strain on the heart and improve overall cardiovascular function.
In addition to its primary applications, Simendan may have potential uses in other areas of medicine, such as critical care or anesthesiology, where its inotropic and vasodilating properties could be advantageous. However, further research and clinical trials would be necessary to establish its efficacy and safety in these contexts.
Check Digit Verification of cas no
The CAS Registry Mumber 131741-08-7 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,3,1,7,4 and 1 respectively; the second part has 2 digits, 0 and 8 respectively.
Calculate Digit Verification of CAS Registry Number 131741-08:
(8*1)+(7*3)+(6*1)+(5*7)+(4*4)+(3*1)+(2*0)+(1*8)=97
97 % 10 = 7
So 131741-08-7 is a valid CAS Registry Number.
InChI:InChI=1/C14H12N6O/c1-9-6-13(21)19-20-14(9)10-2-4-11(5-3-10)17-18-12(7-15)8-16/h2-5,9,17H,6H2,1H3,(H,19,21)/t9-/m0/s1
131741-08-7Relevant articles and documents
Method for obtaining pure enantiomers of a pyridazinone derivative
-
, (2008/06/13)
The present invention relates to a method for preparing optically active enantiomers of [[4-(1,4,5,6-tetrahydro-4-methyl-6-oxo-3-pyridazinyl)phenyl]-hydrazono]propanedinitrile (I), particularly (-) enantiomer of (I). Furthermore, the invention relates to a novel crystalline polymorphic form of the (-) enantiomer.
Novel pyridazinone compounds, compositions thereof and method of use
-
, (2008/06/13)
New heterocyclic compounds of formula I STR1 in which Het means one of following groups; STR2 wherein R11, R13 and R14 mean independently hydrogen, hydroxymethyl or lower alkyl group, Z means S, O or NH; A means valency bond, --CH=CH--, or --CH2 --CH2 --group; R1 and R2 independently means nitro, cyano, halogen, amino, carboxamido, aryl, aroyl, pyridyl, alkoxycarbonyl, acyl or one of following groups; STR3 wherein R6 means hydrogen or lower alkyl group, R8 means lower alkyl, R7 means cyano or COOR10, wherein R10 means hydrogen or lower alkyl or R1 and R2 together form a substituted or unsubstituted 5 or 6 membered ring which may contain 1 or 2 heteroatom N; R3, R4, and R5 mean independently hydrogen, hydroxy or lower alkyl group; Y means N or CH. The compounds may be used in the treatment of congestive heart failure.